Physician profile
Roberto C Chuapoco
NPI 1891883922
$2,182.08
in general payments reported to CMS, 2019-2025
27 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $255 · 2021: $393 · 2022: $303 · 2023: $319 · 2024: $187 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $352.46 | 2022-2025 | Licart, Tirosint, Tirosint |
| Arbor Pharmaceuticals, INC. | $249.56 | 2019-2022 | |
| Novo Nordisk INC | $235.93 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $182.94 | 2019-2024 | Arexvy, Shingrix |
| Amgen INC. | $176.28 | 2019-2021 | |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.62 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.62 | 2019 | |
| Azurity Pharmaceuticals, INC. | $69.59 | 2023 | Edarbi, Horizant |
| Zyla Life Sciences, INC. | $65.24 | 2019 | |
| Forte Bio-Pharma LLC | $63.04 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $51.80 | 2021-2025 | Ztlido |
| Exact Sciences Corporation | $49.47 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $47.78 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $47.01 | 2024-2025 | Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $39.58 | 2023-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $39.55 | 2019 | |
| Lilly USA, LLC | $38.85 | 2023-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $34.11 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $30.12 | 2022 | |
| Pfizer INC. | $28.61 | 2025 | |
| Ethicon US, LLC | $25.11 | 2022 | |
| Dexcom, INC. | $19.74 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $18.01 | 2021 | |
| Amarin Pharma, INC. | $16.51 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.33 | 2021 | |
| Genentech USA, INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Chuapoco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.